Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 16;27(22):7913.
doi: 10.3390/molecules27227913.

Oxidative [3+2]Cycloaddition of Alkynylphosphonates with Heterocyclic N-Imines: Synthesis of Pyrazolo[1,5- a]Pyridine-3-phosphonates

Affiliations

Oxidative [3+2]Cycloaddition of Alkynylphosphonates with Heterocyclic N-Imines: Synthesis of Pyrazolo[1,5- a]Pyridine-3-phosphonates

Igor Philippov et al. Molecules. .

Abstract

A series of pyrazolo[1,5-a]pyridine-3-ylphosphonates were prepared with moderate to good yields by the oxidative [3+2]cycloaddition of 2-subtituted ethynylphosphonates with in situ generated pyridinium-N-imines and their annulated analogs. 2-Aliphatic and 2-Ph acetylenes demonstrate low activity, and the corresponding pyrazolopyridines were achieved with a moderate yield in the presence of 10 mol% Fe(NO3)3·9H2O. At the same time, tetraethyl ethynylbisphosphonate, diethyl 2-TMS- and 2-OPh-ethynylphosphonates possess much greater reactivity and the corresponding pyrazolo[1,5-a]pyridines, and their annulated derivatives were obtained with good to excellent yields without any catalyst. 2-Halogenated ethynylphosphonates also readily reacted with pyridinium-N-imines, forming complex mixtures containing poor amounts of 2-halogenated pyrazolopyridines.

Keywords: alkynes; cycloaddition; heterocycles; iron; oxidation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 3
Scheme 3
Reaction scopes for cycloaddition of N-imines with tetraethyl acetylene bisphosphonate (isolated yields). a The substance was obtained in mixture with 4-metoxypyridine and other unidentified products, yield determined using NMR with CH2Br2 as a standard.
Scheme 5
Scheme 5
Plausible reaction mechanisms.
Figure 1
Figure 1
Biologically active derivatives of pyrazolo[1,5-a]pyridine.
Scheme 1
Scheme 1
Approaches toward pyrazolo[1,5-a]pyridinyl phosphonate synthesis [24,25].
Scheme 2
Scheme 2
Reaction scopes for cycloaddition of N-imines with alkynylphosphonates (isolated yields). a Mixture of diethyl prop-1-yn-1-ylphosphonate and diethyl propa-1,2-diene-1-ylphosphonate was used. b Without the addition of Fe(NO3)3, 0% was observed.
Scheme 4
Scheme 4
Reaction of pyridinium-N-imines with 2-halogenated diethyl acetylenephosphonate.

Similar articles

Cited by

References

    1. Rolan P., Hutchinson M., Johnson K. Ibudilast: A Review of Its Pharmacology, Efficacy and Safety in Respiratory and Neurological Disease. Expert Opin. Pharmacother. 2009;10:2897–2904. doi: 10.1517/14656560903426189. - DOI - PubMed
    1. Ledeboer A., Hutchinson M.R., Watkins L.R., Johnson K.W. Ibudilast (AV-411): A New Class Therapeutic Candidate for Neuropathic Pain and Opioid Withdrawal Syndromes. Expert Opin. Investig. Drugs. 2007;16:935–950. doi: 10.1517/13543784.16.7.935. - DOI - PubMed
    1. Fox R.J., Coffey C.S., Conwit R., Cudkowicz M.E., Gleason T., Goodman A., Klawiter E.C., Matsuda K., McGovern M., Naismith R.T., et al. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. N. Engl. J. Med. 2018;379:846–855. doi: 10.1056/NEJMoa1803583. - DOI - PMC - PubMed
    1. Goodman A.D., Gyang T., Smith A.D. Ibudilast for the Treatment of Multiple Sclerosis. Expert Opin. Investig. Drugs. 2016;25:1231–1237. doi: 10.1080/13543784.2016.1221924. - DOI - PubMed
    1. Nakao S., Nogami M., Iwatani M., Imaeda T., Ito M., Tanaka T., Tawada M., Endo S., Cary D.R., Ohori M., et al. Identification of a Selective DDX3X Inhibitor with Newly Developed Quantitative High-Throughput RNA Helicase Assays. Biochem. Biophys. Res. Commun. 2020;523:795–801. doi: 10.1016/j.bbrc.2019.12.094. - DOI - PubMed

LinkOut - more resources